Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of TerrasilMed ONC for cancer therapy-related dermatologic adverse events
MOH_2024-01-28_013220Phase 2Not yet recruiting
- Sponsor
- ד"ר מור מיודובניק
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allantoin in Erythrodysesthesia syndrome (PPE), toxicoderma (cADR), Hyperpigmentation and 2 more, sponsored by ד"ר מור מיודובניק. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
allantoin
03
Conditions
Erythrodysesthesia syndrome (PPE)toxicoderma (cADR)Hyperpigmentationradiodermatitisdermatitis
Beyond the preview
Go deeper on MOH_2024-01-28_013220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-28_013220.